+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The significance of increasing marker levels in metastatic breast cancer patients with clinically complete remission, partial remission or stable disease during therapy monitoring



The significance of increasing marker levels in metastatic breast cancer patients with clinically complete remission, partial remission or stable disease during therapy monitoring



Anticancer Research 18(6C): 4856




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 033942403

Download citation: RISBibTeXText


Related references

The prognostic significance of increasing marker levels in metastatic breast cancer patients with clinically complete remission, partial remission or stable disease. International Journal of Biological Markers 13(1): 10-15, 1998

Increasing marker levels in metastatic breast cancer patients with clinically complete remission. Tumor Biology 18(SUPPL 2): 41, Sept, 1997

Remission and survival data of metastatic breast cancer patients achieving complete remission with combination chemo immuno therapy. Clinical Research 26(3): 438A, 1978

High-dose therapy and autologous stem cell transplantation as consolidation therapy during first complete remission or partial remission in patients with unfavorable prognosis and advanced stage Hodgkins disease. Blood 90(10 SUPPL 1 PART 1): 114A, Nov 15, 1997

How long should we maintain anti-HER2 therapy for metastatic breast cancer patients with complete remission?. Future Oncology 11(20): 2799-2801, 2016

Cost effectiveness of positron emission tomography in patients with Hodgkin's lymphoma in unconfirmed complete remission or partial remission after first-line therapy. Journal of Clinical Oncology 28(8): 1415-1421, 2010

High-dose therapy with autologous hematopoietic stem cell transplantation for patients with low-grade follicular non-Hodgkins lymphoma in first complete remission or partial remission. Blood 94(10 SUPPL 1 PART 1): 171a, Nov 15, 1999

MAGE-specific T cells detected directly ex-vivo correlate with complete remission in metastatic breast cancer patients after sequential immune-endocrine therapy. Journal for ImmunoTherapy of Cancer 2(1): 32, 2014

Disease-free interval in metastatic breast cancer patients undergoing complete remission: implications of cross-sectional study design and biologic considerations about disease history. Breast Cancer 24(3): 491-492, 2017

Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. Journal of Clinical Oncology 16(5): 1669-1676, 1998

A durable complete remission between two isolated presentations of metastatic breast cancer, the second with intracardiac disease. Clinical Breast Cancer 7(2): 162-163, 2006

Does longer disease-free interval affect the complete remission in metastatic breast cancer?. Breast Cancer 24(3): 490, 2017

Clinical characteristics of patients with metastatic breast cancer with complete remission following systemic treatment. Japanese Journal of Clinical Oncology 28(6): 368-373, 1998

Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. Journal of Clinical Oncology 14(8): 2197-2205, 1996

A case of aromatase inhibitor-tolerant metastatic breast cancer revealing complete remission with high-dose toremifene therapy. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 38(1): 93-96, 2011